Physician profile
Andrea G Espinoza
NPI 1700839495
$654,731.41
in general payments reported to CMS, 2019-2025
21 companies · $258K in 2025
The $258K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,910 · 2020: $2,896 · 2021: $4,493 · 2022: $91K · 2023: $59K · 2024: $229K · 2025: $258K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $455K · Travel and Lodging: $62K · Consulting Fee: $17K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $454,910.80 |
| Travel and Lodging | $62,498.95 |
| Consulting Fee | $17,180.00 |
| Food and Beverage | $11,474.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $389,215.02 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $139,928.25 | 2019-2025 | Dupixent |
| Genzyme Corporation | $122,212.15 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $897.44 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $699.36 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $381.14 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $294.86 | 2019-2021 | |
| Tactile Systems Technology INC | $264.73 | 2022-2025 | Flexitouch Plus, Nimbl |
| Insmed, INC. | $258.52 | 2019-2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $75.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $72.92 | 2021-2023 | |
| Genentech USA, INC. | $71.59 | 2019-2021 | |
| Viatris Specialty LLC | $66.35 | 2025 | Yupelri |
| Philips North America LLC | $61.91 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Baxter Healthcare | $57.84 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $56.43 | 2019-2024 | Yupelri |
| Electromed, INC. | $41.36 | 2022-2025 | Smartvest |
| Advanced Respiratory, INC | $24.00 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $19.32 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.70 | 2023 | |
| Verona Pharma, INC. | $14.52 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.